Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation?

• References

• 1 Juttner CA, To LB, Ho J. et al. Early lympho-hematopoietic recovery after autografting using peripheral blood stem cell in acute nonlymphoblastic leukemia. Transplant Proc 1998; 20: 40-42.
• 2 Stoffel N, Rysler C, Buser A. et al. Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy. Thromb Haemost 2010; 103: 1228-1232.
• 3 Rowbottom AW, Riches PG, Downie C. et al. Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogenic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 635-641.
• 4 Testa S, Manna A, Porcellini A. et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplant 1996; 18: 383-388.
• 5 Nishida T, Hamaguchi M, Hirabayashi N. et al. Intestinal thrombotic microangiopathy after allogenic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1143-1150.
• 6 Hassan M, Ljungman P, Ringden O. et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
• 7 de Jonge ME, Huitema AD, Beijnen JH. et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94: 1226-1230.
• 8 Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant 2008; 41: 229-237.
• 9 Cutler C, Kim HT, Ayanian S. et al. Prediction of veno-acclusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant 2010; 16: 1180-1185.
• 10 Attal M, Huguer F, Rubie H. et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834-2840.
• 11 Nomura S, Ishii K, Inami N. et al. Evaluation of angiopoietins and cell-derived microparticle after stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 766-774.
• 12 Saito H, Maruyama I, Shimazaki S. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31-41.
• 13 Van lersel T, Stroissnig H, Giesen P. et al. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2011; 105: 302-312.
• 14 Kumar S, DeLeve LD, Kamath P. et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598.
• 15 Richardson PG, Elias AD, Krishnan A. et al. Treatment of veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
• 16 Richardson PG, Murakami C, Jin Z. et al. Multi-institutional of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
• 17 Zhou O, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994; 71: 507-510.
• 18 Ho VT, Linden E, Revta C. et al. Hepatic veno-acclusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide. Semin Thromb Hemost 2007; 33: 373-388.
• 19 Ikezoe T, Togitani K, Komatsu N. et al. Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 783-785.
• 20 Sakai M, Ikezoe T, Bandobashi K. et al. Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin. Bone Marrow Transplant 2010; 45: 803-805.
• 21 Abeyama K, Stern DM, Ito Y. et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
• 22 Hatada T, Wada H, Nobori T. et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979.